Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»HealthCare»OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology
    HealthCare

    OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology

    Marie JonesBy Marie JonesJuly 26, 2024No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    OmniGuide Holdings, Inc. (OGH) is thrilled to announce the successful completion of a groundbreaking patient study for its innovative iSTONE™ software, a laser-guided system designed for real-time automatic target identification in endoscopic stone lithotripsy. This advancement marks a significant milestone in the treatment of urolithiasis, promising a new era of precision and safety in kidney stone management.

    In August 2022, the German Federal Ministry of Education and Research recognized the potential of this pioneering technology, awarding LISA Laser Products GmbH, a subsidiary of OmniGuide Holdings based in Germany, a prestigious grant (Grant No. 13GW0628) to develop theiSTONE system further. The novel optical feedback technology at the heart of iSTONE has demonstrated a significant reduction in energy required during lithotripsy procedures in a porcine animal model, thereby minimizing the heat load and potential temperature increase in the kidney. This innovation not only preserves the integrity of the organ but also protects it from permanent postoperative damage.

    The results from the animal study are compelling, showing the potential for a reduction of over 50% in the energy applied and the risk of kidney damage compared to the traditional Gold Standard Holmium Therapy.1 “Our unique approach underscores our patient-focused mission and is set to redefine laser-assisted lithotripsy,” stated Tullio Cappelletto, Global Director of Marketing and Sales at OmniGuide Holdings.

    The OmniGuide Digital Innovation Institute, with its team of exceptional developers and engineering specialists, continues to push the boundaries of medical technology. “Their commitment to advancing patient care has led to the creation of iSTONE, a testament to the company’s dedication to innovation and excellence in healthcare,” stated Robert Allen, CFO of OmniGuide Holdings.

    The findings from the patient study, eagerly anticipated by the medical community, will be unveiled in the forthcoming months. OmniGuide Holdings is poised to lead the way in enhancing the safety, efficiency, and outcomes of kidney stone treatment, solidifying its position at the forefront of medical innovation.

    For more information about OmniGuide Holdings and the iSTONE™ technology, please visit https://www.omni-guide.com/news.

    1 Schlager, D., Schulte, A., Schütz, J., Brandenburg, A., Schell, C., Lamrini, S., Vogel, M., Teichmann, H.-O., & Miernik, A. (2021). Laser-guided real-time automatic target identification for endoscopic stone lithotripsy: a two-arm in vivo porcine comparison study. World Journal of Urology, 39, 2719-2726. https://doi.org/10.1007/s00345-020-03452-0

    Contact Information
    Tullio Cappelletto
    tcappelletto@omni-guide.com

    SOURCE: OmniGuide Holdings, Inc.

    OmniGuide Holdings Inc
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleKucingko Berhad Debuts on ACE Market with Clawsome Opening Price of RM0.805
    Next Article CITIC Resources Announces its 2024 Interim Results

    Related Posts

    Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease

    October 5, 2026

    Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China’s NMPA, Driving Continued Commercial Momentum

    October 2, 2026

    ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines’ CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment Option

    September 21, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Latest News

    • ComplianceQuest and Zolon PCS Selected to Modernize U.S. Food and Drug Administration (FDA) Enterprise Quality Management System
    • Stagwell Launches New Global Media Agency, Stagwell Media
    • U.S. Polo Assn. Celebrates an Outstanding 2026 European Polo Season
    • JCB Launches Premium Card Issuing Initiative for Affluent Customers in ASEAN Under Strategic Comprehensive Partnership with MUFG Bank
    • TMX Group Thanksgiving Holiday Market Closures
    • Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada
    • Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada
    • Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts
    • TIPAK Marks Path to Leadership in Packaging Solutions Following Listing on SET
    • Chervon Names Daniel L. Abbott Director of Sales – Western U.S.A.
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.